Status:
COMPLETED
Empagliflozin in Heart Failure Dialysis Patients
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Heart Failure
Hemodialysis
Eligibility:
All Genders
Phase:
NA
Brief Summary
Empagliflozin is not still approved for glomerular filtration rate \< 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflo...
Detailed Description
Heart failure dialysis patients with residual renal function will be followed up on Empagliflozin based on echocardiographic parameters, pro-brain natriuretic peptide levels, diuresis volume, and seru...
Eligibility Criteria
Inclusion
- Heart failure on dialysis with residual renal function
Exclusion
- Dialysis patients with no residual urine
Key Trial Info
Start Date :
June 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 3 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05967156
Start Date
June 1 2023
End Date
June 3 2025
Last Update
June 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nooshin Dalili
Tehran, Iran, 1666663421